Seth M (@_sethmorton) header
Seth M (@_sethmorton) profile picture

building discovery foundation models i dream of exploring exoplanets.

San Francisco
Joined November 2023
Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)Photo by Seth M (@_sethmorton)
pov: the last thing that you see before being mansplained continual learning
2
8
564
hiring great people as a founder must be so hard how do you convince people just as if not more smart than you to come work for you
1
2
172
What is all the hate for Veritasium all of a sudden because he is going to be spending more time with his family? The man has been educating people for more than a decade and this is how you treat him? Just because he decided to bring in a team to help him? Please just be mad at anything. Just be happy to watch the videos I know you're not paying for.
Hopefully. You either die a hero, or do whatever this channel did over the last few years.
4
2
53
3,312
Today we’re thrilled to announce JAM-2 — the first AI model capable of generating drug-quality antibodies straight from the computer, with industry-leading success rates. > Drug-like affinities: Picomolar to single-digit nanomolar antibody binders for half of 26 targets while testing <45 designs each. > Unlocking hard targets: Up to 11% success rate for direct on-cell GPCR binders; top antibody hits in the single-digit nanomolar range. > Unprecedented epitope breadth: JAM-2 routinely designed antibodies that hit 30–70% of user-defined epitopes, now enabling intentional design of biology — not chance discovery. > Drug-like developability: Over 50% of antibody designs passed core industry developability criteria with zero optimization. > Massive leverage: A four-person team prosecuted 16 targets in parallel in < 1 month. JAM-2 is the first de novo antibody design capability ready for front-line use in drug discovery, matching or surpassing traditional discovery approaches. We’re already deploying JAM-2 with multiple large pharma partners and seeing excellent results. If you’re interested in partnering on molecule development or accessing JAM-2, contact [email protected]. Read more in our whitepaper (link below)
21
110
41
497
201,902
Patterns of Under-Supply and Over-Supply of Belief in Early Stage Founders & Companies…
9
1
1
15
7,282